Summit Therapeutics Inc.
SMMT
$18.22
-$0.69-3.65%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -368.59% | -361.42% | -107.50% | 64.01% | 67.09% |
| Total Depreciation and Amortization | 29.90% | -4.59% | -35.56% | -55.05% | -87.30% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 967.68% | 1,067.92% | 241.87% | -88.18% | -89.12% |
| Change in Net Operating Assets | -9.47% | 17.83% | 31.82% | 3,099.81% | 703.15% |
| Cash from Operations | -138.87% | -112.20% | -84.66% | -85.13% | -116.64% |
| Capital Expenditure | -299.21% | -304.92% | -605.06% | -8.59% | -9.48% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -100.00% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 273.08% | 332.74% | -183.81% | 65.09% | 64.82% |
| Cash from Investing | 272.76% | 332.11% | -184.37% | 65.06% | 64.79% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 67.55% | -- | -- | -305.09% | -205.84% |
| Issuance of Common Stock | -90.85% | 39.92% | 6,539.74% | 328.87% | 362.07% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -1,306.82% |
| Cash from Financing | -95.11% | -8.08% | 5,540.71% | 340.66% | -31.52% |
| Foreign Exchange rate Adjustments | -96.41% | 34.62% | -84.40% | -102.15% | -81.36% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 105.92% | 2,116.44% | 1,705.40% | 105.85% | 171.61% |